HC Wainwright Issues Negative Forecast for NovoCure Earnings

NovoCure Limited (NASDAQ:NVCR) – Stock analysts at HC Wainwright lowered their FY2029 earnings per share (EPS) estimates for NovoCure in a report released on Thursday, July 23rd. HC Wainwright analyst E. Bodnar now expects that the medical equipment provider will earn $1.90 per share for the year, down from their previous estimate of $1.95. HC Wainwright has a “Buy” rating and a $52.00 price objective on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.52) per share.

A number of other research firms have also commented on NVCR. Evercore reaffirmed an “outperform” rating on shares of NovoCure in a research report on Friday, May 1st. Weiss Ratings upgraded NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 1st. JPMorgan Chase & Co. assumed coverage on NovoCure in a research report on Monday, July 13th. They set a “neutral” rating and a $17.00 price objective for the company. Wells Fargo & Company increased their price objective on NovoCure from $13.50 to $17.00 and gave the stock an “equal weight” rating in a report on Monday, May 4th. Finally, Wedbush reissued a “neutral” rating and issued a $18.00 price objective on shares of NovoCure in a research report on Thursday, April 16th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $24.80.

NovoCure Trading Up 28.4%

Shares of NASDAQ NVCR opened at $19.99 on Friday. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of -13.07 and a beta of 0.94. NovoCure has a twelve month low of $9.82 and a twelve month high of $20.55. The company has a quick ratio of 2.70, a current ratio of 2.90 and a debt-to-equity ratio of 0.71. The company’s fifty day moving average is $16.64 and its 200-day moving average is $14.12.

NovoCure (NASDAQ:NVCR) last posted its earnings results on Thursday, July 23rd. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.20. The company had revenue of $183.58 million during the quarter, compared to analyst estimates of $172.44 million. NovoCure had a negative return on equity of 50.82% and a negative net margin of 25.66%.The company’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.36) EPS.

Institutional Investors Weigh In On NovoCure

A number of institutional investors have recently made changes to their positions in the company. Empowered Funds LLC acquired a new position in shares of NovoCure in the fourth quarter valued at approximately $33,000. Kestra Advisory Services LLC acquired a new stake in NovoCure during the 4th quarter worth approximately $49,000. Larson Financial Group LLC lifted its holdings in NovoCure by 662.1% during the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 3,562 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in NovoCure by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock valued at $70,000 after purchasing an additional 1,120 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in NovoCure in the 1st quarter valued at $87,000. Institutional investors own 84.61% of the company’s stock.

Insider Transactions at NovoCure

In other news, CEO Frank X. Leonard sold 34,273 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $17.93, for a total value of $614,514.89. Following the transaction, the chief executive officer directly owned 459,520 shares of the company’s stock, valued at $8,239,193.60. This represents a 6.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeryl L. Hilleman sold 2,945 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total transaction of $46,442.65. Following the sale, the director owned 13,861 shares of the company’s stock, valued at approximately $218,587.97. This represents a 17.52% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 51,943 shares of company stock valued at $893,171. Corporate insiders own 5.52% of the company’s stock.

Trending Headlines about NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported Q2 EPS of -$0.13, topping the consensus estimate of -$0.33, while revenue of $183.58 million also beat expectations and rose 15.6% year over year.
• Positive Sentiment: The company raised FY 2026 revenue guidance to $710 million-$725 million, above the prior Street estimate, signaling improving business momentum.
• Positive Sentiment: Investor enthusiasm increased around potential FDA approval for the company’s brain therapy candidate, which added to the bullish outlook and helped drive the stock to a record high. Novocure (NVCR) Hits New High on Optimistic Outlook, FDA Approval Hopes
• Positive Sentiment: HC Wainwright kept a Buy rating and raised its price target to $52, which suggests Wall Street still sees substantial upside from current levels.
• Neutral Sentiment: HC Wainwright trimmed its FY2029 EPS forecast slightly to $1.90 from $1.95, a modest revision that does not appear to have changed the firm’s constructive stance.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.